查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1630989

全球硬化療法市場：市場規模、佔有率和趨勢分析（按藥物、類型、應用、地區和細分市場，2025-2030 年）

Sclerotherapy Market Size, Share & Trends Analysis Report By Agents (Detergents, Chemical Irritants, Osmotic Agents), By Type (Ultrasound Sclerotherapy), By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

硬化療法市場的成長與趨勢：

根據 Grand View Research, Inc. 的最新報告，全球硬化療法市場規模預計到 2030 年將達到 15 億美元，2025 年至 2030 年期間的複合年成長率為 4.4%。硬化療法是一種非侵入性手術，廣泛用於治療網狀靜脈、腿部毛細血管擴張和靜脈曲張的主要治療方法。此手術包括將溶液（硬化劑）直接注射到受影響的靜脈中，有助於治療疼痛、潮紅、腫脹和痙攣等相關症狀，並使其縮小並最終消失。應用部位的更好接觸、微創技術的可用性、皮膚病學的進步以及靜脈曲張和老年人口發病率的增加等因素正在推動市場的成長。

用於治療靜脈曲張的硬化劑分為清洗、高滲透壓劑/滲透劑和化學促效劑。十四烷基硫酸鈉 (Sotradecol) 和聚多卡醇 (Asclera)、嗎啉 (Scleromate) 和乙醇胺油酸酯 (Ethamoline) 等藥物都是 FDA核准的硬化劑，用於治療和減輕靜脈損傷的影響。根據血管外科學會的數據，已開發國家超過 33.0% 的女性和約 17.0% 的男性因毛細血管擴張或靜脈曲張而就醫，僅在美國就影響到 35.0% 的人。

如果不及時治療，這種疾病會導致嚴重的健康問題，包括慢性疼痛、深層靜脈栓塞症、皮膚潰瘍和冠狀動脈疾病。根據 NCBI 統計，20.0% 的成年人在一生中的某個階段會患上靜脈曲張，老年人群和女性的發病率更高。預計這些因素將推動市場成長。然而，該手術的副作用，如色素沉著、毛髮脫落、疤痕和某些患者的過敏反應，可能會阻礙市場的成長。

硬化療法市場：分析概述

  • 由於獲得 FDA 高度核准、血栓形成風險低、有效性以及在醫生中很受歡迎，清洗劑部門在 2024 年佔據了市場主導地位，收益佔有率為 43.5%。
  • 由於發泡硬化療法比液體硬化療法具有更高的領域曝光度和更好的效果，預計在預測期內泡沫硬化療法領域將快速成長。
  • 北美硬化療法市場佔據全球市場主導地位，2024 年的收入佔有率為 44.5%，這歸因於該地區對新技術的需求不斷增加、大量關鍵參與者、靜脈曲張患病率不斷上升以及先進的醫療保健基礎設施。
  • 預計預測期內亞太地區硬化療法市場將達到最高的 5.7% 複合年成長率。

目錄

第1章 分析方法及範圍

第 2 章執行摘要

3. 硬化療法市場：變數、趨勢和範圍

  • 市場聯動展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制分析
  • 商業環境分析
    • 產業分析：波特五力分析
    • PESTLE分析

第 4 章 硬化療法市場：藥物業務分析

  • 按藥物類型市場佔有率（2024 年和 2030 年）
  • 細分儀表板：按藥物
  • 依藥物類型分類的市場規模預測及趨勢分析（2018-2030年）
  • 清潔劑
  • 化學刺激物
  • 滲透劑

第 5 章硬化療法市場：按類型進行的業務分析

  • 按類型市場佔有率（2024 年和 2030 年）
  • 細分儀表板：按類型
  • 按類型分類的市場規模預測及趨勢分析（2018-2030）
  • 超音波硬化療法
  • 液體硬化療法
  • 泡沫硬化療法

第 6 章 硬化療法市場：按應用進行的業務分析

  • 按應用分類的市場佔有率（2024 年和 2030 年）
  • 細分儀表板：依用途
  • 按應用分類的市場規模預測和趨勢分析（2018-2030 年）
  • 靜脈曲張
  • 淋巴管畸形
  • 痔瘡
  • 浮腫

第 7 章硬化療法市場：按地區分類的估計和趨勢分析

  • 各地區市場佔有率（2024 年及 2030 年）
  • 市場儀表板：按地區
  • 市場規模預測及趨勢分析（2018-2030年）
  • 北美洲
    • 按國家/地區分類（2018-2030 年）
    • 美國
    • 加拿大
  • 歐洲
    • 按國家/地區分類（2018-2030 年）
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類（2018-2030 年）
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 按國家/地區分類（2018-2030 年）
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭格局

  • 市場參與企業：概覽
  • 公司市場地位分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • LGM Pharma
    • Troikaa
    • Viatris Inc.
    • Omega Pharmaceuticals Pvt. Ltd.
    • Merz Pharma
    • ENDO-FLEX GmbH.
    • Perrigo Company plc
    • Medi-Globe GmbH
    • Medtronic
    • AngioDynamics
Product Code: GVR-4-68039-010-4

Sclerotherapy Market Growth & Trends:

The global sclerotherapy market size is estimated to reach USD 1.50 billion by 2030, expanding at a CAGR of 4.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Sclerotherapy is a non-invasive procedure that is widely used as a primary treatment for reticular veins, leg telangiectasias, and varicose veins. The procedure comprises injecting a solution (sclerosing agents or sclerosants) straight into the affected veins, which causes them to shrink and eventually disappear and assist in treating related symptoms such as aching, burning, swelling, and cramping. Factors like the better exposure to the site of application, utilization of less-invasive technologies, advances in dermatology, and increasing geriatric population with an incidence of varicose veins are fuelling the market growth.

Sclerosing agents used for the treatment of varicose veins are segmented into detergents, hyperosmolar/ osmotic agents, and chemical irritants. Agents like Sodium tetradecyl sulfate (Sotradecol) and Polidocanol (Asclera), Sodium morrhuate (Scleromate), Ethanolamine Oleate (Ethamoline) are all FDA approved sclerosants used to treat and reduce the effect of vein damage. According to the Society of Vascular surgery, more than 33.0% of women and about 17.0% of men consult a doctor for telangiectasias and varicose veins in industrialized countries, affecting up to 35.0% of people in the U.S. alone.

This condition, if left untreated can cause severe health problems such as chronic pain, deep vein clots, skin ulcers, and coronary ailments. According to NCBI, 20.0% of all adults will get varicose veins at some point in their lives and the prevalence is higher among the aging population and women. These factors are expected to boost the market growth. However, the side effects of this procedure such as hyperpigmentation and matting, scarring, and allergic reactions in some patients might hinder the market growth.

Sclerotherapy Market Report Highlights:

  • The detergents segment dominated the market with a revenue share of 43.5% in 2024 owing to high approvals by the FDA, low risk of clot formation, effectiveness, and its popularity among doctors
  • The foam sclerotherapy segment is anticipated to grow fast over the forecast period due to better exposure to the onsite and results than liquid sclerotherapy
  • North America sclerotherapy market dominated the global with a revenue share of 44.5% in 2024 owing to increasing demand for new technologies, a large pool of key players, rising prevalence of varicose veins, and advanced healthcare infrastructure in the region
  • Asia Pacific sclerotherapy market is expected to register the highest CAGR of 5.7% over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Agents
    • 1.2.2. Type
    • 1.2.3. Application
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Sclerotherapy Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Sclerotherapy Market: Agents Business Analysis

  • 4.1. Agents Market Share, 2024 & 2030
  • 4.2. Agents Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Agents, 2018 to 2030 (USD Billion)
  • 4.4. Detergents
    • 4.4.1. Detergents Market, 2018 - 2030 (USD Billion)
  • 4.5. Chemical Irritants
    • 4.5.1. Chemical Irritants Market, 2018 - 2030 (USD Billion)
  • 4.6. Osmotic Agents
    • 4.6.1. Osmotic Agents Market, 2018 - 2030 (USD Billion)

Chapter 5. Sclerotherapy Market: Type Business Analysis

  • 5.1. Type Market Share, 2024 & 2030
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2018 to 2030 (USD Billion)
  • 5.4. Ultrasound Sclerotherapy
    • 5.4.1. Ultrasound Sclerotherapy Market, 2018 - 2030 (USD Billion)
  • 5.5. Liquid Sclerotherapy
    • 5.5.1. Liquid Sclerotherapy Market, 2018 - 2030 (USD Billion)
  • 5.6. Foam Sclerotherapy
    • 5.6.1. Foam Sclerotherapy Market, 2018 - 2030 (USD Billion)

Chapter 6. Sclerotherapy Market: Application Business Analysis

  • 6.1. Application Market Share, 2024 & 2030
  • 6.2. Application Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Billion)
  • 6.4. Varicose Veins
    • 6.4.1. Varicose Veins Market, 2018 - 2030 (USD Billion)
  • 6.5. Malformed Lymph Vessels
    • 6.5.1. Malformed Lymph Vessels Market, 2018 - 2030 (USD Billion)
  • 6.6. Hemorrhoids
    • 6.6.1. Hemorrhoids Market, 2018 - 2030 (USD Billion)
  • 6.7. Hydroceles
    • 6.7.1. Hydroceles Market, 2018 - 2030 (USD Billion)

Chapter 7. Sclerotherapy Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Mexico
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Mexico Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.4. Argentina
      • 7.7.4.1. Key Country Dynamics
      • 7.7.4.2. Regulatory Framework
      • 7.7.4.3. Competitive Insights
      • 7.7.4.4. Argentina Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Sclerotherapy Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Sclerotherapy Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. LGM Pharma
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Agents Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Troikaa
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Agents Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Viatris Inc.
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Agents Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Omega Pharmaceuticals Pvt. Ltd.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Agents Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Merz Pharma
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Agents Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. ENDO-FLEX GmbH.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Agents Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Perrigo Company plc
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Agents Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Medi-Globe GmbH
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Agents Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Medtronic
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Agents Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. AngioDynamics
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Agents Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global sclerotherapy market, by region, 2018 - 2030 (USD Billion)
  • Table 4 Global sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 5 Global sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 6 Global sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 7 North America sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 9 North America sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 10 North America sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 11 U.S. sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 12 U.S. sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 14 Canada sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 15 Canada sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 16 Canada sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 17 Europe sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 18 Europe sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 19 Europe sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 20 Europe sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 21 UK sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 22 UK sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 23 UK sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 24 Germany sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 25 Germany sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 26 Germany sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 27 France sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 28 France sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 29 France sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 30 Italy sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 31 Italy sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 32 Italy sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 33 Spain sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 34 Spain sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Spain sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 36 Norway sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 37 Norway sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Norway sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 39 Denmark sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 40 Denmark sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Denmark sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 42 Sweden sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 43 Sweden sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 44 Sweden sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 45 Asia Pacific sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 46 Asia Pacific sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 47 Asia Pacific sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 48 Asia Pacific sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 49 Japan sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 50 Japan sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 51 Japan sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 52 China sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 53 China sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 54 China sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 55 India sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 56 India sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 57 India sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 58 Australia sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 59 Australia sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 60 Australia sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 61 South Korea sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 62 South Korea sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 63 South Korea sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 64 Thailand sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 65 Thailand sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 66 Thailand sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 67 Latin America sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 68 Latin America sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 69 Latin America sclerotherapy market, by type, 2018 - 2030 (USD Billion
  • Table 70 Latin America sclerotherapy market, by application, 2018 - 2030 (USD Billion
  • Table 71 Brazil sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 72 Brazil sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Brazil sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 74 Mexico sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 75 Mexico sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Mexico sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 77 Argentina sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 78 Argentina sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Argentina sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 80 Middle East & Africa sclerotherapy market, by country, 2018 - 2030 (USD Billion)
  • Table 81 Middle East & Africa sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 82 Middle East & Africa sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Middle East & Africa sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 84 South Africa sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 85 South Africa sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 86 South Africa sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 87 Saudi Arabia sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 88 Saudi Arabia sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Saudi Arabia sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 90 UAE sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 91 UAE sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 92 UAE sclerotherapy market, by application, 2018 - 2030 (USD Billion)
  • Table 93 Kuwait sclerotherapy market, by agents, 2018 - 2030 (USD Billion)
  • Table 94 Kuwait sclerotherapy market, by type, 2018 - 2030 (USD Billion)
  • Table 95 Kuwait sclerotherapy market, by application, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Sclerotherapy market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Agents outlook (USD Billion)
  • Fig. 10 Type outlook (USD Billion)
  • Fig. 11 Application outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Sclerotherapy market dynamics
  • Fig. 14 Sclerotherapy market: Porter's five forces analysis
  • Fig. 15 Sclerotherapy market: PESTLE analysis
  • Fig. 16 Sclerotherapy market: Agents segment dashboard
  • Fig. 17 Sclerotherapy market: Agents market share analysis, 2024 & 2030
  • Fig. 18 Detergents market, 2018 - 2030 (USD Billion)
  • Fig. 19 Chemical irritants market, 2018 - 2030 (USD Billion)
  • Fig. 20 Osmotic agents market, 2018 - 2030 (USD Billion)
  • Fig. 21 Sclerotherapy market: Type segment dashboard
  • Fig. 22 Sclerotherapy market: Type market share analysis, 2024 & 2030
  • Fig. 23 Ultrasound sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 24 Liquid sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 25 Foam sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 26 Sclerotherapy market: Application segment dashboard
  • Fig. 27 Sclerotherapy market: Application market share analysis, 2024 & 2030
  • Fig. 28 Varicose veins market, 2018 - 2030 (USD Billion)
  • Fig. 29 Malformed lymph vessels market, 2018 - 2030 (USD Billion)
  • Fig. 30 Hemorrhoids market, 2018 - 2030 (USD Billion)
  • Fig. 31 Hydroceles market, 2018 - 2030 (USD Billion)
  • Fig. 32 Sclerotherapy market revenue, by region
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 39 Europe sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 40 UK country dynamics
  • Fig. 41 UK sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 42 Germany country dynamics
  • Fig. 43 Germany sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 44 France country dynamics
  • Fig. 45 France sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 46 Italy country dynamics
  • Fig. 47 Italy sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 48 Spain country dynamics
  • Fig. 49 Spain sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 50 Norway country dynamics
  • Fig. 51 Norway sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 52 Denmark country dynamics
  • Fig. 53 Denmark sclerotherapy market, 2018 - 2030 (USD Billion
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 56 Asia Pacific sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 57 Japan country dynamics
  • Fig. 58 Japan sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 59 China country dynamics
  • Fig. 60 China sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 61 India country dynamics
  • Fig. 62 India sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 63 South Korea country dynamics
  • Fig. 64 South Korea sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 67 Thailand country dynamics
  • Fig. 68 Thailand sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 69 Latin America sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 70 Brazil country dynamics
  • Fig. 71 Brazil sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 72 Mexico country dynamics
  • Fig. 73 Mexico sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 76 MEA sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 83 Kuwait country dynamics
  • Fig. 84 Kuwait sclerotherapy market, 2018 - 2030 (USD Billion)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework